PRESIDENT HAS SERVED AS A REVIEWER FOR THE ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) STUDY SECTION FOR THE NIH

PDX Pharma’s President has served as a reviewer for the ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) Study Section for the National Institute of Health (NIH) held on June 28, 2017.

pdx news

  • PDX Pharma met phase I SBIR milestones and is approved for starting the phase II SBIR project by the National Cancer Institute on 06/01/2018

    5/25/2018
    read more

  • President serves as the guest editor for the Bioengineering’s special issue “Nanoparticles in Therapeutic Applications”

    5/22/2018
    read more

  • President has served as a reviewer for the ZRG1 IMST-L (55) ‘Innovative Research in Cancer Nanotechnology’ (R01) Study Section for the NIH

    5/22/2018
    read more

Copyright © 2017 PDX Pharmaceuticals, LLC. All rights reserved